Início/Ações/GMAB

GMAB

USD

Genmab A/S ADS

$28.975+0.435 (1.524%)

Preço em tempo real

Healthcare

Biotecnologia

Dinamarca

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado

Fundamentos da empresa

Estatísticas de negociação

Métricas de mercado

Abertura

$28.540

Máximo

$29.390

Mínimo

$28.510

Volume

2.92M

Fundamentos da empresa

Capitalização de mercado

17.8B

Setor

Biotecnologia

País

Denmark

Estatísticas de negociação

Volume médio

2.00M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $17.235Atual $28.975Máximo $33.65

Notícias relacionadas

3/11/2025 · 14:05

BusinessWire

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of

Ver mais

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

15/10/2025 · 10:29

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab with a Buy and maintains $40 price target.

Ver mais

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

14/10/2025 · 10:23

GlobeNewswire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,

Ver mais